MYOSITIS
Clinical trials for MYOSITIS explained in plain language.
Never miss a new study
Get alerted when new MYOSITIS trials appear
Sign up with your email to follow new studies for MYOSITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for myositis patients: long-term drug safety trial underway
Disease control ENROLLING_BY_INVITATIONThis study looks at the long-term safety of a drug called efgartigimod for adults with a group of muscle diseases known as idiopathic inflammatory myopathy (IIM). Only people who completed an earlier study of this drug can join. Participants will receive the drug for up to 51 mon…
Matched conditions: MYOSITIS
Phase: PHASE3 • Sponsor: argenx • Aim: Disease control
Last updated May 17, 2026 02:39 UTC
-
Early IVIg boost may tame muscle disease before it disables
Disease control OngoingThis study tests whether adding intravenous immunoglobulin (IVIg) to standard steroid treatment early in myositis leads to better improvement than steroids alone. Myositis causes muscle inflammation and weakness. The trial includes 44 adults diagnosed within the past year with ce…
Matched conditions: MYOSITIS
Phase: PHASE2, PHASE3 • Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) • Aim: Disease control
Last updated May 17, 2026 02:38 UTC
-
New drug hope for rare muscle disease
Disease control OngoingThis study tests a new medicine called empasiprubart against a placebo in adults with dermatomyositis, a rare disease causing muscle weakness and skin rashes. About 3 participants will receive the drug or placebo for 25 weeks, then be followed for safety over a year. The goal is …
Matched conditions: MYOSITIS
Phase: PHASE2 • Sponsor: argenx • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New drug shows promise for rare muscle disease
Disease control OngoingThis study tests a drug called nipocalimab against a placebo in 36 people with active myositis, a condition causing muscle inflammation and weakness. The goal is to see if nipocalimab can improve muscle strength and reduce disease activity while allowing lower steroid use. Partic…
Matched conditions: MYOSITIS
Phase: PHASE2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
Promising skin drug trial for rare muscle disease pulled before start
Disease control TerminatedThis study aimed to test deucravacitinib, a pill already approved for psoriasis, in adults with dermatomyositis or juvenile dermatomyositis that did not respond to standard treatments. The goal was to see if the drug could improve muscle and skin symptoms. However, the study was …
Matched conditions: MYOSITIS
Phase: PHASE2 • Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) • Aim: Disease control
Last updated May 14, 2026 12:01 UTC
-
Rare disease pregnancy study withdrawn before start
Knowledge-focused TerminatedThis study was designed to track pregnancies in women with rare autoimmune diseases like lupus, arthritis, and scleroderma. The goal was to learn about complications and improve care. However, the study was withdrawn before enrolling any participants, so no results are available.
Matched conditions: MYOSITIS
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated May 11, 2026 20:53 UTC